http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005164975-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-33 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4965 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-655 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076 |
| filingDate | 2004-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c3ad37ba3773ffa75f66c08e8710b9a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6dd7f1b3360d0b6a3a31bf155c8d627 |
| publicationDate | 2005-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2005164975-A1 |
| titleOfInvention | Purine receptor inhibition as a therapeutic strategy in spinal cord and brain |
| abstract | The present invention is directed to a method of treating a subject with acute spinal cord injury by administering a purine receptor antagonist to the subject under conditions effective to treat spinal cord injury. The purine receptor antagonist inhibits P2X purine receptor activation. The inhibition of P2X purine receptor activation can also be used in conjunction with methods of treating a subject with spinal cord ischemia resulting from stroke or vascular insult, interruption, or mechanical injury, treating a subject with ischemic or traumatic insults of brain tissue in regions expressing P2X receptors, and for inhibiting ATP-triggered brain or spinal cord cell death. |
| priorityDate | 2003-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 70.